Ascentage Pharma Group International (OTCMKTS:ASPHF) Sees Significant Decline in Short Interest

Ascentage Pharma Group International (OTCMKTS:ASPHF) was the recipient of a significant decline in short interest in February. As of February 27th, there was short interest totaling 20,702 shares, a decline of 87.6% from the February 12th total of 167,300 shares. Based on an average trading volume of 4 shares, the days-to-cover ratio is currently 5,175.5 days. Based on an average trading volume of 4 shares, the days-to-cover ratio is currently 5,175.5 days.

Ascentage Pharma Group International Price Performance

Shares of ASPHF remained flat at $8.48 during mid-day trading on Tuesday. The stock’s 50-day simple moving average is $8.48 and its 200 day simple moving average is $8.98. Ascentage Pharma Group International has a 12 month low of $7.50 and a 12 month high of $10.65.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International (OTCMKTS:ASPHF) is a clinical-stage biopharmaceutical company headquartered in Beijing, China, with a strategic presence in the United States. The company focuses on the discovery and development of targeted small-molecule therapies that modulate programmed cell death, leveraging a deep understanding of the Bcl-2 family of proteins.

Ascentage’s core activities center on the research and development of apoptosis regulators, including both Bcl-2 selective and dual Bcl-2/Bcl-xL inhibitors.